PaTH Forward: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of TransCon PTH in Adult Hypoparathyroidism
暂无分享,去创建一个
L. Rejnmark | C. Marcocci | L. Hofbauer | M. Rubin | U. Pagotto | D. Karpf | M. Brod | B. Clarke | Susanne Pihl | A. Palermo | T. Vokes | P. Schwarz | Intekhab Ahmed | Alden Smith | Aliya A. Khan | D. Markova | A. Shu | Erik Eriksen | Sanchita Mourya | B. Clarke
[1] L. McLeod,et al. Psychometric validation of the Hypoparathyroidism Patient Experience Scales (HPES) , 2021, Journal of Patient-Reported Outcomes.
[2] D. Karpf,et al. A Randomized Double‐Blind Placebo‐Controlled First‐In‐Human Phase 1 Trial of TransCon PTH in Healthy Adults , 2019, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[3] D. Karpf,et al. Design and Preclinical Development of TransCon PTH, an Investigational Sustained‐Release PTH Replacement Therapy for Hypoparathyroidism , 2019, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[4] N. Watts,et al. Safety and Efficacy of 5 Years of Treatment With Recombinant Human Parathyroid Hormone in Adults With Hypoparathyroidism , 2019, The Journal of clinical endocrinology and metabolism.
[5] R. Eastell,et al. Bone turnover markers to explain changes in lumbar spine BMD with abaloparatide and teriparatide: results from ACTIVE , 2019, Osteoporosis International.
[6] J. Bilezikian,et al. Signs and Symptoms of Hypoparathyroidism. , 2018, Endocrinology and metabolism clinics of North America.
[7] J. Bilezikian,et al. Recombinant Human Parathyroid Hormone Effect on Health-Related Quality of Life in Adults With Chronic Hypoparathyroidism , 2017, The Journal of clinical endocrinology and metabolism.
[8] S. Singer,et al. Quality of life in patients with hypoparathyroidism receiving standard treatment: a systematic review , 2017, Endocrine.
[9] L. Rejnmark,et al. Management of Hypoparathyroidism: Present and Future. , 2016, The Journal of clinical endocrinology and metabolism.
[10] S. Cremers,et al. Therapy of Hypoparathyroidism With PTH(1-84): A Prospective Six Year Investigation of Efficacy and Safety. , 2016, The Journal of clinical endocrinology and metabolism.
[11] B. Clarke,et al. Understanding the burden of illness associated with hypoparathyroidism reported among patients in the PARADOX study. , 2014, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.
[12] M. Rubin,et al. Use of parathyroid hormone in hypoparathyroidism , 2013, Journal of Endocrinological Investigation.
[13] Michael Vrla,et al. Long-term follow-up of patients with hypoparathyroidism. , 2012, The Journal of clinical endocrinology and metabolism.
[14] P. Albert,et al. Synthetic human parathyroid hormone 1-34 replacement therapy: a randomized crossover trial comparing pump versus injections in the treatment of chronic hypoparathyroidism. , 2012, The Journal of clinical endocrinology and metabolism.
[15] S. Cremers,et al. PTH(1–84) administration reverses abnormal bone‐remodeling dynamics and structure in hypoparathyroidism , 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[16] L. Rejnmark,et al. The effect of adding PTH(1–84) to conventional treatment of hypoparathyroidism: A randomized, placebo‐controlled study , 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[17] H. Koeffler,et al. The role of the vitamin D endocrine system in health and disease. , 1989, The New England journal of medicine.
[18] M. Haussler,et al. Basic and clinical concepts related to vitamin D metabolism and action (second of two parts). , 1977, The New England journal of medicine.
[19] H. DeLuca. The kidney as an endocrine organ for the production of 1,25-dihydroxyvitamin D 3 , a calcium-mobilizing hormone. , 1973, The New England journal of medicine.